Stresscopin and stresscopin-related peptides (urocortin III and urocortin II respectively) are part of the corticotrophin-releasing factor (CRF) family, which also includes CRF and urocortin. CRFs are peptide hormones, which play biological roles in generating the stress response by acting at CRF1 and CRF2 receptors. They contribute to the pathophysiology of stress-related disorders such as anxiety, depression and eating disorders in addition to cardiac and inflammatory disorders.
Stresscopin and stresscopin-related peptides are involved in responses to physiological stress and in the regulation of cardiovascular, gastrointestinal systems and inflammation. By agonizing corticotropin-releasing factor (CRF) type 2 receptor, stresscopin improves cardiac output and heart rate and therefore, the peptide has gathered attention as a potential therapeutic for heart failure patients.
MEET BACHEM: SIMON SCHLÄPPI, GROUP LEADER BUSINESS APPLICATIONS
This month the spotlight is on Simon Schläppi, Group Leader Business Applications at Bachem AG. Learn about Simon’s role at Bachem and what he likes to do in his free time.
This month's highlights include news about a new drug discovery that could be useful to combat inflammation of all varieties and shows promise in fighting acute respiratory illnesses such as COVID-19, a substance capable of controlling citrus greening disease, the synthesis and folding of the trefoil factor peptide 1 (TFF1), which is a key player in mucosal protection and about a transferrin receptor binding protein that can ferry cargo across the blood brain barrier.
All information is compiled to the best of our knowledge. We cannot be made liable for any possible errors or misprints. Some products may be restricted in certain countries.
